# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Lake Street analyst Frank Takkinen maintains ClearPoint Neuro (NASDAQ:CLPT) with a Buy and raises the price target from $11 ...
ClearPoint Neuro (NASDAQ:CLPT) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0....
Aspen Neuroscience Announces MRI-Guided Transplantation Approach for ASPIRO Clinical Trial with the ClearPoint® Navigation System
ClearPoint Neuro (NASDAQ:CLPT) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0....